aluates Reports

$ 0.0

Automative

Global Hepatic Encephalopathy (HE) Therapeutics Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-36V13252

Global Hepatic Encephalopathy HE Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Hepatic Encephalopathy (HE) Therapeutics Market Research Report 2025

Code: QYRE-Auto-36V13252

Report

September 2025

Pages:64

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

ASKA Pharmaceutical

Cosmo Pharmaceuticals

Mallinckrodt plc

Valeant

Hepatic Encephalopathy (HE) Therapeutics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Hepatic Encephalopathy (HE) Therapeutics Market

The global market for Hepatic Encephalopathy (HE) Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Hepatic Encephalopathy (HE) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatic Encephalopathy (HE) Therapeutics.

The Hepatic Encephalopathy (HE) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hepatic Encephalopathy (HE) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hepatic Encephalopathy (HE) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Hepatic Encephalopathy (HE) Therapeutics Market Report

Report Metric	Details
Report Name	Hepatic Encephalopathy (HE) Therapeutics Market
CAGR	5%
Segment by Type	Lactulose Rifaximin Neomycin Probiotics Thiamine
Segment by Application	Acute Liver Failure Liver Cirrhosis
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt, Valeant
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hepatic Encephalopathy (HE) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Hepatic Encephalopathy (HE) Therapeutics Market report?

Ans: The main players in the Hepatic Encephalopathy (HE) Therapeutics Market are ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt, Valeant

What are the Application segmentation covered in the Hepatic Encephalopathy (HE) Therapeutics Market report?

Ans: The Applications covered in the Hepatic Encephalopathy (HE) Therapeutics Market report are Acute Liver Failure, Liver Cirrhosis

What are the Type segmentation covered in the Hepatic Encephalopathy (HE) Therapeutics Market report?

Ans: The Types covered in the Hepatic Encephalopathy (HE) Therapeutics Market report are Lactulose, Rifaximin, Neomycin, Probiotics, Thiamine

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Lactulose

1.2.3 Rifaximin

1.2.4 Neomycin

1.2.5 Probiotics

1.2.6 Thiamine

1.3 Market by Application

1.3.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Acute Liver Failure

1.3.3 Liver Cirrhosis

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Perspective (2020-2031)

2.2 Global Hepatic Encephalopathy (HE) Therapeutics Growth Trends by Region

2.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Hepatic Encephalopathy (HE) Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Hepatic Encephalopathy (HE) Therapeutics Market Dynamics

2.3.1 Hepatic Encephalopathy (HE) Therapeutics Industry Trends

2.3.2 Hepatic Encephalopathy (HE) Therapeutics Market Drivers

2.3.3 Hepatic Encephalopathy (HE) Therapeutics Market Challenges

2.3.4 Hepatic Encephalopathy (HE) Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Hepatic Encephalopathy (HE) Therapeutics Players by Revenue

3.1.1 Global Top Hepatic Encephalopathy (HE) Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Hepatic Encephalopathy (HE) Therapeutics Revenue

3.4 Global Hepatic Encephalopathy (HE) Therapeutics Market Concentration Ratio

3.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hepatic Encephalopathy (HE) Therapeutics Revenue in 2024

3.5 Global Key Players of Hepatic Encephalopathy (HE) Therapeutics Head office and Area Served

3.6 Global Key Players of Hepatic Encephalopathy (HE) Therapeutics, Product and Application

3.7 Global Key Players of Hepatic Encephalopathy (HE) Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type

4.1 Global Hepatic Encephalopathy (HE) Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Type (2026-2031)

5 Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application

5.1 Global Hepatic Encephalopathy (HE) Therapeutics Historic Market Size by Application (2020-2025)

5.2 Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size (2020-2031)

6.2 North America Hepatic Encephalopathy (HE) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2020-2025)

6.4 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size (2020-2031)

7.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2020-2025)

7.4 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size (2020-2031)

9.2 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 ASKA Pharmaceutical

11.1.1 ASKA Pharmaceutical Company Details

11.1.2 ASKA Pharmaceutical Business Overview

11.1.3 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Introduction

11.1.4 ASKA Pharmaceutical Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2020-2025)

11.1.5 ASKA Pharmaceutical Recent Development

11.2 COSMO PHARMACEUTICALS

11.2.1 COSMO PHARMACEUTICALS Company Details

11.2.2 COSMO PHARMACEUTICALS Business Overview

11.2.3 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Introduction

11.2.4 COSMO PHARMACEUTICALS Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2020-2025)

11.2.5 COSMO PHARMACEUTICALS Recent Development

11.3 Mallinckrodt

11.3.1 Mallinckrodt Company Details

11.3.2 Mallinckrodt Business Overview

11.3.3 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Introduction

11.3.4 Mallinckrodt Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2020-2025)

11.3.5 Mallinckrodt Recent Development

11.4 Valeant

11.4.1 Valeant Company Details

11.4.2 Valeant Business Overview

11.4.3 Valeant Hepatic Encephalopathy (HE) Therapeutics Introduction

11.4.4 Valeant Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2020-2025)

11.4.5 Valeant Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

ASKA Pharmaceutical

Cosmo Pharmaceuticals

Mallinckrodt plc

Valeant

List of Tables

Table 1. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Lactulose

Table 3. Key Players of Rifaximin

Table 4. Key Players of Neomycin

Table 5. Key Players of Probiotics

Table 6. Key Players of Thiamine

Table 7. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Region (2020-2025)

Table 11. Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Region (2026-2031)

Table 13. Hepatic Encephalopathy (HE) Therapeutics Market Trends

Table 14. Hepatic Encephalopathy (HE) Therapeutics Market Drivers

Table 15. Hepatic Encephalopathy (HE) Therapeutics Market Challenges

Table 16. Hepatic Encephalopathy (HE) Therapeutics Market Restraints

Table 17. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Players (2020-2025)

Table 19. Global Top Hepatic Encephalopathy (HE) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatic Encephalopathy (HE) Therapeutics as of 2024)

Table 20. Ranking of Global Top Hepatic Encephalopathy (HE) Therapeutics Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by Hepatic Encephalopathy (HE) Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of Hepatic Encephalopathy (HE) Therapeutics, Headquarters and Area Served

Table 23. Global Key Players of Hepatic Encephalopathy (HE) Therapeutics, Product and Application

Table 24. Global Key Players of Hepatic Encephalopathy (HE) Therapeutics, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2020-2025)

Table 28. Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2026-2031)

Table 30. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2020-2025)

Table 32. Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2026-2031)

Table 34. North America Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 49. ASKA Pharmaceutical Company Details

Table 50. ASKA Pharmaceutical Business Overview

Table 51. ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Product

Table 52. ASKA Pharmaceutical Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2020-2025) & (US$ Million)

Table 53. ASKA Pharmaceutical Recent Development

Table 54. COSMO PHARMACEUTICALS Company Details

Table 55. COSMO PHARMACEUTICALS Business Overview

Table 56. COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Product

Table 57. COSMO PHARMACEUTICALS Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2020-2025) & (US$ Million)

Table 58. COSMO PHARMACEUTICALS Recent Development

Table 59. Mallinckrodt Company Details

Table 60. Mallinckrodt Business Overview

Table 61. Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Product

Table 62. Mallinckrodt Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2020-2025) & (US$ Million)

Table 63. Mallinckrodt Recent Development

Table 64. Valeant Company Details

Table 65. Valeant Business Overview

Table 66. Valeant Hepatic Encephalopathy (HE) Therapeutics Product

Table 67. Valeant Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2020-2025) & (US$ Million)

Table 68. Valeant Recent Development

Table 69. Research Programs/Design for This Report

Table 70. Key Data Information from Secondary Sources

Table 71. Key Data Information from Primary Sources

Table 72. Authors List of This Report

List of Figures

Figure 1. Hepatic Encephalopathy (HE) Therapeutics Picture

Figure 2. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. Lactulose Features

Figure 5. Rifaximin Features

Figure 6. Neomycin Features

Figure 7. Probiotics Features

Figure 8. Thiamine Features

Figure 9. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Application: 2024 VS 2031

Figure 11. Acute Liver Failure Case Studies

Figure 12. Liver Cirrhosis Case Studies

Figure 13. Hepatic Encephalopathy (HE) Therapeutics Report Years Considered

Figure 14. Global Hepatic Encephalopathy (HE) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Hepatic Encephalopathy (HE) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Region: 2024 VS 2031

Figure 17. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Players in 2024

Figure 18. Global Top Hepatic Encephalopathy (HE) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatic Encephalopathy (HE) Therapeutics as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Hepatic Encephalopathy (HE) Therapeutics Revenue in 2024

Figure 20. North America Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2020-2031)

Figure 22. United States Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2020-2031)

Figure 26. Germany Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Share by Region (2020-2031)

Figure 34. China Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2020-2031)

Figure 42. Mexico Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2020-2031)

Figure 46. Turkey Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. ASKA Pharmaceutical Revenue Growth Rate in Hepatic Encephalopathy (HE) Therapeutics Business (2020-2025)

Figure 50. COSMO PHARMACEUTICALS Revenue Growth Rate in Hepatic Encephalopathy (HE) Therapeutics Business (2020-2025)

Figure 51. Mallinckrodt Revenue Growth Rate in Hepatic Encephalopathy (HE) Therapeutics Business (2020-2025)

Figure 52. Valeant Revenue Growth Rate in Hepatic Encephalopathy (HE) Therapeutics Business (2020-2025)

Figure 53. Bottom-up and Top-down Approaches for This Report

Figure 54. Data Triangulation

Figure 55. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions